Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
control group:Symptomatic treatment of Western medicine + Jinghua Jiedu decoction placebo
Sponsors
The First Affiliated Hospital to Henan University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: ? Patients with mild COVID-19; ? Age 18-80 years old; ? Voluntarily accept treatment and sign informed consent.
Exclusion criteria
Exclusion criteria: ? delirious, consciousness disorder, dementia, all kinds of mental patients; ? Pregnant and lactating women; ? Patients with active pulmonary tuberculosis, pulmonary abscess and chronic respiratory failure; ? Patients with tumor; ? Patients with severe liver and kidney diseases; ? patients with severe cardiovascular and cerebrovascular diseases; ? those who are taking part in clinical trials of other drugs and are known to be allergic to the treatment drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nucleic acid turning negative time;Nucleic acid conversion rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time/rate of clinical symptom remission;Time/rate of the abatement of fever;rate to the normal/heavy;Cumulative incidence of adverse events; | — |
Countries
China
Contacts
Public ContactLi Suyun
The First Affiliated Hospital to Henan University of Chinese Medicine
Outcome results
None listed